Positive Data on Sanofi’s Aubagio – Analyst Blog

By | October 24, 2012
0 Comment

Sanofi ( SNY ) and its subsidiary Genzyme recently presented positive data on its oral treatment for relapsing forms of multiple sclerosis (RMS), Aubagio (teriflunomide). The company

Read More:
Positive Data on Sanofi’s Aubagio – Analyst Blog

Related posts:

  1. Positive Data on CYTK’s Tirasemtiv – Analyst Blog
  2. SNY’s Dengue Vaccine Data Published – Analyst Blog
  3. Myriad Teams Up with Sanofi – Analyst Blog
  4. Encouraging Data on Glaxo’s Drug – Analyst Blog